Modulation of 11β-Hydroxysteroid Dehydrogenase (11βHSD) Activity Biomarkers and Pharmacokinetics of PF-00915275, a Selective 11βHSD1 Inhibitor
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Context: 11β-Hydroxysteroid dehydrogenase type 1 (11βHSD1) is a promising target for the treatment of type 2 diabetes mellitus. 11βHSD1 catalyzes the intracrine conversion of inactive cortisone to the active glucocorticoid cortisol. Objective: Demonstrating inhibition of 11βHSD1 is challenging because there is no accessible way to directly assess the enzyme activity in vivo. Thus, it was proposed to assess the enzyme activity, in an indirect fashion, using two biomarker methods: the prednisolone generation study (conversion of oral prednisone to prednisolone in plasma) and the ratio of cortisol and cortisone metabolites in urine. Design: This was a phase 1, double-blind, placebo-controlled, randomized, multiple-dose study. Setting: The study was conducted in a clinical research unit. Participants: Sixty healthy adult volunteers participated in the study. Intervention: Oral doses of PF-00915275 (0.3–15 mg) and prednisone (10 mg) were administered during the study. Main Outcome Measures: Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-00915275, a selective 11βHSD1 inhibitor, were measured. Results: Overall, multiple oral doses of PF-00915275 were safe and well tolerated. After oral administration, PF-00915275 was rapidly absorbed, slowly eliminated, and generally displayed dose-proportional increases in exposure. At the 15-mg dose, mean exposure to prednisolone was reduced by 37%, and there was a dose-dependent fall in the 5α-tetrahydrocortisol + 5β-tetrahydrocortisol to tetrahydrocortisone ratio with maximum inhibition of 26% after 14 d. The urinary free cortisol to urinary free cortisone ratio, an indicator of 11βHSD2 inhibition, did not change. Conclusion: PF-00915275 was safe at all doses tested. The results of the prednisolone generation test and the urinary metabolite ratios confirm that PF-00915275 is a selective 11βHSD1 inhibitor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A transgenic model of visceral obesity and the metabolic syndrome
Masuzaki, H., Paterson, J., Shinyama, H., Morton, N. M., Mullins, J. J., Seckl, J. R., & Flier, J. S. (2001) · Science · doi:10.1126/science.1066285 · Cited by 1,766 · cited 3×
“Compared with current antidiabetic agents on the market, an 11 HSD1 inhibitor may ameliorate a number of comorbidities that occur in diabetic patients including hypertension (13), dyslipidemia, and visceral adiposity and therefore could be used to treat aspects of the metabolic syndrome (8, 9).”
BackgroundMethodInfluentialMorton, N. M., Paterson, J. M., Masuzaki, H., Holmes, M. C., Staels, B., Fievet, C., Walker, B. R., Flier, J. S., Mullins, J. J., & Seckl, J. R. (2004) · Diabetes · doi:10.2337/diabetes.53.4.931 · Cited by 512
Franco, O. H., Steyerberg, E. W., Hu, F. B., Mackenbach, J., & Nusselder, W. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.11.1145 · Cited by 400
Quality of Diabetes Care in U.S. Academic Medical Centers
Grant, R. W., Buse, J. B., Meigs, J. B., & for the University HealthSystem Consortium (UHC) Diabetes Benchmarking Project Team (2005) · Diabetes Care · doi:10.2337/diacare.28.2.337 · Cited by 311
Cited by
11β-hydroxysteroid dehydrogenase 1: translational and therapeutic aspects
Gathercole, L. L., Lavery, G. G., Morgan, S. A., Cooper, M. S., Sinclair, A. J., Tomlinson, J. W., & Stewart, P. M. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1050 · Cited by 196
Self-citationKuroda, K., Venkatakrishnan, R., Salker, M. S., Lucas, E. S., Shaheen, F., Kuroda, M., Blanks, A., Christian, M., Quenby, S., & Brosens, J. J. (2013) · Molecular Endocrinology · doi:10.1210/me.2012-1247 · Cited by 63
Rogers, S. L., Hughes, B. A., Jones, C. A., Freedman, L., Smart, K., Taylor, N., Stewart, P. M., Shackleton, C. H. L., Krone, N. P., Blissett, J., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3254 · Cited by 25
Self-citation
Metadata
- Authors
- Courtney, R., Stewart, P. M., Toh, M., Ndongo, M.-N., Calle, R. A., & Hirshberg, B.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-02-01
- Volume
- 93
- Issue
- 2
- Pages
- 550-556
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2016025876
- Cited by
- 90
- References
- 4
- FWCI
- 4.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modulation of 11β-Hydroxysteroid Dehydrogenase (11βHSD) Activity Biomarkers and Pharmacokinetics of PF-00915275, a Selective 11βHSD1 Inhibitor. https://app.cochat.ai/papers/10.1210/jc.2007-1912
- The paper
- Courtney, R., Stewart, P. M., Toh, M., Ndongo, M.-N., Calle, R. A., & Hirshberg, B. (2008). Modulation of 11β-Hydroxysteroid Dehydrogenase (11βHSD) Activity Biomarkers and Pharmacokinetics of PF-00915275, a Selective 11βHSD1 Inhibitor. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2007-1912
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.